ULTRAGENYX PHARMACEUTICAL IN (RARE) Stock Fundamental Analysis

NASDAQ:RARE • US90400D1081

23.43 USD
-0.45 (-1.88%)
Last: Feb 12, 2026, 10:06 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

Taking everything into account, RARE scores 2 out of 10 in our fundamental rating. RARE was compared to 523 industry peers in the Biotechnology industry. Both the profitability and financial health of RARE have multiple concerns. RARE is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year RARE has reported negative net income.
  • RARE had a negative operating cash flow in the past year.
  • RARE had negative earnings in each of the past 5 years.
  • RARE had a negative operating cash flow in each of the past 5 years.
RARE Yearly Net Income VS EBIT VS OCF VS FCFRARE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200M -400M -600M

1.2 Ratios

  • With a Return On Assets value of -48.71%, RARE perfoms like the industry average, outperforming 52.01% of the companies in the same industry.
  • RARE has a Return On Equity of -6330.70%. This is amonst the worse of the industry: RARE underperforms 81.45% of its industry peers.
Industry RankSector Rank
ROA -48.71%
ROE -6330.7%
ROIC N/A
ROA(3y)-41.44%
ROA(5y)-32.95%
ROE(3y)-214.63%
ROE(5y)-141.85%
ROIC(3y)N/A
ROIC(5y)N/A
RARE Yearly ROA, ROE, ROICRARE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200

1.3 Margins

  • RARE has a Gross Margin of 84.69%. This is amongst the best in the industry. RARE outperforms 87.38% of its industry peers.
  • In the last couple of years the Gross Margin of RARE has remained more or less at the same level.
  • RARE does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 84.69%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.3%
GM growth 5Y-1.12%
RARE Yearly Profit, Operating, Gross MarginsRARE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50K -100K -150K -200K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. Health

2.1 Basic Checks

  • RARE does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for RARE has been increased compared to 1 year ago.
  • Compared to 5 years ago, RARE has more shares outstanding
  • RARE has a better debt/assets ratio than last year.
RARE Yearly Shares OutstandingRARE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
RARE Yearly Total Debt VS Total AssetsRARE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

  • Based on the Altman-Z score of -4.68, we must say that RARE is in the distress zone and has some risk of bankruptcy.
  • RARE has a Altman-Z score of -4.68. This is in the lower half of the industry: RARE underperforms 60.42% of its industry peers.
  • RARE has a Debt/Equity ratio of 83.39. This is a high value indicating a heavy dependency on external financing.
  • The Debt to Equity ratio of RARE (83.39) is worse than 81.64% of its industry peers.
Industry RankSector Rank
Debt/Equity 83.39
Debt/FCF N/A
Altman-Z -4.68
ROIC/WACCN/A
WACC11.84%
RARE Yearly LT Debt VS Equity VS FCFRARE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B

2.3 Liquidity

  • A Current Ratio of 1.89 indicates that RARE should not have too much problems paying its short term obligations.
  • With a Current ratio value of 1.89, RARE is not doing good in the industry: 76.86% of the companies in the same industry are doing better.
  • A Quick Ratio of 1.74 indicates that RARE should not have too much problems paying its short term obligations.
  • RARE's Quick ratio of 1.74 is on the low side compared to the rest of the industry. RARE is outperformed by 77.25% of its industry peers.
Industry RankSector Rank
Current Ratio 1.89
Quick Ratio 1.74
RARE Yearly Current Assets VS Current LiabilitesRARE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an nice 8.19% over the past year.
  • The Revenue has grown by 20.63% in the past year. This is a very strong growth!
  • Measured over the past years, RARE shows a very strong growth in Revenue. The Revenue has been growing by 40.13% on average per year.
EPS 1Y (TTM)8.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-29.29%
Revenue 1Y (TTM)20.63%
Revenue growth 3Y16.82%
Revenue growth 5Y40.13%
Sales Q2Q%14.65%

3.2 Future

  • Based on estimates for the next years, RARE will show a very strong growth in Earnings Per Share. The EPS will grow by 23.29% on average per year.
  • Based on estimates for the next years, RARE will show a very strong growth in Revenue. The Revenue will grow by 28.67% on average per year.
EPS Next Y9.99%
EPS Next 2Y17.29%
EPS Next 3Y21.2%
EPS Next 5Y23.29%
Revenue Next Year20.78%
Revenue Next 2Y19.9%
Revenue Next 3Y28.26%
Revenue Next 5Y28.67%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
RARE Yearly Revenue VS EstimatesRARE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 1B 2B 3B
RARE Yearly EPS VS EstimatesRARE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 5 -5 10 -10

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • RARE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RARE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RARE Price Earnings VS Forward Price EarningsRARE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RARE Per share dataRARE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6

4.3 Compensation for Growth

  • A more expensive valuation may be justified as RARE's earnings are expected to grow with 21.20% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.29%
EPS Next 3Y21.2%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • RARE does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ULTRAGENYX PHARMACEUTICAL IN

NASDAQ:RARE (2/12/2026, 10:06:50 AM)

23.43

-0.45 (-1.88%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-04
Earnings (Next)02-12
Inst Owners103.06%
Inst Owner Change-1.18%
Ins Owners3.24%
Ins Owner Change-0.98%
Market Cap2.26B
Revenue(TTM)630.60M
Net Income(TTM)-579.83M
Analysts85.19
Price Target66.86 (185.36%)
Short Float %9.62%
Short Ratio3.28
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-16.03%
Min EPS beat(2)-43.75%
Max EPS beat(2)11.68%
EPS beat(4)2
Avg EPS beat(4)-8.27%
Min EPS beat(4)-43.75%
Max EPS beat(4)11.68%
EPS beat(8)5
Avg EPS beat(8)-2.83%
EPS beat(12)6
Avg EPS beat(12)-4.05%
EPS beat(16)6
Avg EPS beat(16)-13.56%
Revenue beat(2)1
Avg Revenue beat(2)-2.46%
Min Revenue beat(2)-5.94%
Max Revenue beat(2)1.02%
Revenue beat(4)2
Avg Revenue beat(4)-1.49%
Min Revenue beat(4)-5.94%
Max Revenue beat(4)4.02%
Revenue beat(8)5
Avg Revenue beat(8)1.05%
Revenue beat(12)6
Avg Revenue beat(12)-1.01%
Revenue beat(16)7
Avg Revenue beat(16)-1.78%
PT rev (1m)-20.16%
PT rev (3m)-21.77%
EPS NQ rev (1m)5.19%
EPS NQ rev (3m)6.47%
EPS NY rev (1m)2.75%
EPS NY rev (3m)-10.85%
Revenue NQ rev (1m)4.32%
Revenue NQ rev (3m)5.17%
Revenue NY rev (1m)1.08%
Revenue NY rev (3m)0.61%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.58
P/FCF N/A
P/OCF N/A
P/B 246.81
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-5.94
EYN/A
EPS(NY)-3.96
Fwd EYN/A
FCF(TTM)-4.83
FCFYN/A
OCF(TTM)-4.62
OCFYN/A
SpS6.54
BVpS0.09
TBVpS-2.16
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -48.71%
ROE -6330.7%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 84.69%
FCFM N/A
ROA(3y)-41.44%
ROA(5y)-32.95%
ROE(3y)-214.63%
ROE(5y)-141.85%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.3%
GM growth 5Y-1.12%
F-Score2
Asset Turnover0.53
Health
Industry RankSector Rank
Debt/Equity 83.39
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 58.7%
Cap/Sales 3.29%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.89
Quick Ratio 1.74
Altman-Z -4.68
F-Score2
WACC11.84%
ROIC/WACCN/A
Cap/Depr(3y)346.02%
Cap/Depr(5y)389.65%
Cap/Sales(3y)18.19%
Cap/Sales(5y)18.31%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)8.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-29.29%
EPS Next Y9.99%
EPS Next 2Y17.29%
EPS Next 3Y21.2%
EPS Next 5Y23.29%
Revenue 1Y (TTM)20.63%
Revenue growth 3Y16.82%
Revenue growth 5Y40.13%
Sales Q2Q%14.65%
Revenue Next Year20.78%
Revenue Next 2Y19.9%
Revenue Next 3Y28.26%
Revenue Next 5Y28.67%
EBIT growth 1Y-1.54%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year4.56%
EBIT Next 3Y22.99%
EBIT Next 5YN/A
FCF growth 1Y15.72%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y7.39%
OCF growth 3YN/A
OCF growth 5YN/A

ULTRAGENYX PHARMACEUTICAL IN / RARE FAQ

What is the ChartMill fundamental rating of ULTRAGENYX PHARMACEUTICAL IN (RARE) stock?

ChartMill assigns a fundamental rating of 3 / 10 to RARE.


Can you provide the valuation status for ULTRAGENYX PHARMACEUTICAL IN?

ChartMill assigns a valuation rating of 1 / 10 to ULTRAGENYX PHARMACEUTICAL IN (RARE). This can be considered as Overvalued.


How profitable is ULTRAGENYX PHARMACEUTICAL IN (RARE) stock?

ULTRAGENYX PHARMACEUTICAL IN (RARE) has a profitability rating of 1 / 10.


What is the financial health of ULTRAGENYX PHARMACEUTICAL IN (RARE) stock?

The financial health rating of ULTRAGENYX PHARMACEUTICAL IN (RARE) is 2 / 10.


Is the dividend of ULTRAGENYX PHARMACEUTICAL IN sustainable?

The dividend rating of ULTRAGENYX PHARMACEUTICAL IN (RARE) is 0 / 10 and the dividend payout ratio is 0%.